Physician profile
Abdulmalek Sabbagh
NPI 1427018837
$6,060.23
in general payments reported to CMS, 2019-2025
25 companies · $879 in 2025
The $879 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $728 · 2021: $1,322 · 2022: $931 · 2023: $744 · 2024: $793 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,210.93 | 2019-2025 | Haegarda, Andembry |
| Astrazeneca Pharmaceuticals LP | $838.12 | 2019-2025 | Farxiga, Brilinta, Airsupra |
| Novartis Pharmaceuticals Corporation | $811.95 | 2019-2025 | |
| Boston Scientific Corporation | $642.10 | 2019-2025 | Ekosonic, Wolverine Coronary Cutting Balloon, Avvigo Guidance System |
| Merck Sharp & Dohme LLC | $539.90 | 2021-2025 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $518.84 | 2019-2024 | Xarelto |
| Abbott Laboratories | $306.26 | 2019-2024 | Amplatzer Amulet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.49 | 2019-2024 | Jardiance |
| Pfizer INC. | $225.52 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $134.85 | 2019-2023 | Eliquis |
| Amgen INC. | $130.53 | 2019-2022 | |
| Novo Nordisk INC | $118.55 | 2020-2025 | Wegovy, Ozempic |
| Kestra Medical Technology Services, INC. | $71.74 | 2025 | Assure Wcd |
| Shockwave Medical, INC | $43.77 | 2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave M5+ |
| Xeris Pharmaceuticals, INC. | $38.55 | 2023-2024 | Gvoke Hypopen |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $34.86 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.16 | 2025 | Xifaxan |
| Heartflow, INC. | $23.83 | 2024 | |
| Vital Connect, INC | $23.11 | 2022 | |
| Lilly USA, LLC | $19.59 | 2022 | |
| Insulet Corporation | $17.07 | 2021 | |
| Cardiovascular Systems INC. | $16.30 | 2022 | |
| Esperion Therapeutics, INC. | $15.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.77 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdulmalek Sabbagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.